Revolution Medicines climbs after pricing upsized $2.0B stock and convertible-note deal
Revolution Medicines shares are higher after the company priced an upsized $2.0 billion financing: 10.56 million shares at $142 and $500 million of 0.50% convertible senior notes due 2033. The stock is trading above the offering price, signaling demand for added balance-sheet firepower as its late-stage RAS-oncology programs advance.
1. What’s moving the stock today
Revolution Medicines (RVMD) is moving higher after it priced a large, upsized capital raise. The company set a public offering price of $142.00 for 10,563,381 shares (about $1.5 billion gross proceeds) and priced $500.0 million of 0.50% convertible senior notes due 2033, for total gross proceeds of roughly $2.0 billion.
2. Why investors are bidding shares up
Even though equity and convertible financings can pressure shares, RVMD is trading above the $142 offering price, which points to supportive demand and a view that the added capital strengthens execution capacity. The transaction increases financial flexibility for a late-stage oncology pipeline and reduces near-term funding risk, a key investor focus for pre-revenue biotech names.
3. Key deal terms and near-term timing
The equity offering is expected to settle on April 16, 2026, and the convertible notes are expected to settle on April 17, 2026. The notes are 0.50% convertible senior notes due 2033, adding a lower-coupon funding layer but introducing potential future dilution depending on the conversion price and stock performance.
4. What to watch next
Traders will be focused on post-settlement price action as the market digests the new share supply and on any incremental detail about use of proceeds and trial cadence. Another watch item is the stock’s behavior around conversion-related levels over time, since convert structures can influence hedging flows and volatility as RVMD trades further above the deal price.